A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515539-31-00

Acronym

MK-1167-008

Enrollment

Registered

2025-03-18

Start date

2025-04-01

Completion date

Unknown

Last updated

2025-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer’s disease dementia

Brief summary

Change From Baseline in the Alzheimer's Disease Assessment Scale-11-item Cognitive Subscale (ADAS-Cog11) Total Score at Week 24, Number of participants who experience one or more adverse events (AEs), Number of participants who discontinue study intervention due to an AE

Detailed description

Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC) Overall Score at Week 24, Change From Baseline in The Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Total Score at Week 24, Change From Baseline in the ADAS-Cog11 Total Score at Week 12, ADCS-CGIC Overall Score at Week 12, Change From Baseline in the ADCS-ADL Total Score at Week 12

Interventions

DRUGPlacebo to MK-1167

DRUGMK-1167

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change From Baseline in the Alzheimer's Disease Assessment Scale-11-item Cognitive Subscale (ADAS-Cog11) Total Score at Week 24, Number of participants who experience one or more adverse events (AEs), Number of participants who discontinue study intervention due to an AE	—

Secondary

Measure	Time frame
Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC) Overall Score at Week 24, Change From Baseline in The Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Total Score at Week 24, Change From Baseline in the ADAS-Cog11 Total Score at Week 12, ADCS-CGIC Overall Score at Week 12, Change From Baseline in the ADCS-ADL Total Score at Week 12	—

Countries

Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026